Table 4.
Clinical studies that investigating molecular features, MSI-H and CIMP-H in signet ring cell colorectal cancer
| Study | n | Stage | Histology | KRAS (n, %) | NRAS (n, %) | BRAF (n, %) | PIK3CA (n, %) | FBXW7 (n, %) | APC (n, %) | TP53 (n, %) | SMAD4 (n, %) | MSI-H (n, %) | CIMP-H (n, %) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Present study | 35 | IV | Confirmed ≥ 50% SC | 4/35 (11.4%) | 0/35 (0.0%) | 3/35 (8.6%) | 1/35 (2.9%) | 1/35 (2.9%) | 1/35 (2.9%) | 21/35 (60.0%) | 5/35 (14.3%) | 4/33 (12.1%) | 1/3 (33.3%) |
| Kawabata Y, 199924 | 10 | II–IV | Not confirmed | 1/9 (11.0%) | – | – | – | – | – | – | – | 3/10 (30.0%) | – |
| Kakar S, 20054 | 45 | I–IV | Confirmed ≥ 50% SC | – | – | – | – | – | – | – | – | 12/45 (26.7%) | – |
| Ogino S, 200625 | 9 | NA | Confirmed ≥ 50% SC | 0/8 (0.0%) | – | 2/9 (22.0%) | – | – | – | – | – | 2/8 (25.0%) | – |
| Kakar S, 201217 | 33 | I–IV | Confirmed ≥ 50% SC | 16/30 (53.3%) | – | 9/27 (33.3%) | – | – | – | – | – | 8/33 (24.2%) | 16/33 (48.5%) |
| Hartman DJ, 201316 | 53 | I–IV | Confirmed ≥ 50% SC | – | – | 16/50 (32.0%) | – | – | – | – | – | 23/53 (43.4%) | – |
| Inamura K, 201515 | 20 | I–IV | Confirmed ≥ 50% SC | 1/17 (5.9%) | – | 6/17 (35.3%) | 1/16 (6.2%) | – | – | – | – | 5/17 (29.4%) | 5/17 (29.4%) |
| Nitsche U, 201612 | 160 | I–IV | Not confirmed | – | – | – | – | – | – | – | – | 1/5 (20.0%) | – |
| Wei Q, 20167 | 39 | I–IV | Confirmed ≥ 50% SC | 5/33 (15.2%) | – | 1/33 (3.0%) | – | – | – | – | – | – | – |
| Yalcin S, 201728 | 9 | II–IV | Confirmed ≥ 50% SC | – | – | 4/9 (36.4%) | – | – | – | – | – | – | – |
| Nam JY, 201827 | 5 | NA | Confirmed > 50% SC | 2/5 (40.0%) | 0/5 (0.0%) | – | 0/5 (0.0%) | 1/5 (20.0%) | 1/5 (20.0%) | 2/5 (40.0%) | 1/5 (20.0%) | – | – |